Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels

This genetic study did something a drug trial cannot yet do: it used people born with naturally low lipoprotein(a) to forecast what an effective Lp(a)-lowering drug should achieve — and how much lowering it would take.

Across more than 112,000 people, genetically lower Lp(a) was associated with substantially less coronary disease (29 percent lower per standard-deviation reduction), and also with less peripheral vascular disease, stroke, heart failure, and aortic stenosis — but no effect on diabetes or cancer, a reassuring specificity. A crucial practical number emerged: matching the heart benefit of a standard LDL-lowering (1 mmol/L) would require a large absolute Lp(a) reduction — about 100 mg/dL. That has guided how aggressively Lp(a) drugs must lower the particle to matter.

The study both confirmed Lp(a)‘s causal role across multiple diseases and set the bar that the Lp(a)-lowering trials now underway are aiming to clear.

We rate the evidence strong. A large, well-conducted Mendelian randomization study, it is among the key works defining Lp(a) as a drug target and quantifying what success would require.